

**EUTHANASIA III SOLUTION- euthanasia injection, solution**  
**Covetrus North America**

-----  
**EUTHANASIA-III SOLUTION**

ANADA 200-280, Approved by the FDA

**For dogs only.**

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

**DESCRIPTION:** A non-sterile solution containing pentobarbital sodium and phenytoin sodium as the active ingredients. Rhodamine B, a bluish-red fluorescent dye, is included in the formulation to help distinguish it from parenteral drugs intended for therapeutic use. Although the solution is not sterile, benzyl alcohol, a bacteriostat, is included to retard the growth of microorganisms.

Each mL contains: Active ingredients: 390 mg pentobarbital sodium (barbituric acid derivative), 50 mg phenytoin sodium, Inactive ingredients: 10% ethyl alcohol, 18% propylene glycol, 0.003688 mg rhodamine B, 2% benzyl alcohol (preservative), purified water q.s. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH.

**ACTIONS:** Euthanasia III Solution contains two active ingredients which are chemically compatible but pharmacologically different. Each ingredient acts in such a manner so as to cause humane, painless, and rapid euthanasia. Euthanasia is due to cerebral death in conjunction with respiratory arrest and circulatory collapse. Cerebral death occurs prior to cessation of cardiac activity.

When administered intravenously, pentobarbital sodium produces rapid anesthetic action. There is a smooth and rapid onset of unconsciousness. At the lethal dose, there is depression of vital medullary respiratory and vasomotor centers.

When administered intravenously, phenytoin sodium produces toxic signs of cardiovascular collapse and/or central nervous system depression. Hypotension occurs when the drug is administered rapidly.

**PHARMACODYNAMIC ACTIVITY:** The sequence of events leading to humane, painless, and rapid euthanasia following intravenous injection of EUTHANASIA-III solution is similar to that following intravenous injection of pentobarbital sodium or other barbituric derivatives. Within seconds, unconsciousness is induced with simultaneous collapse of the dog. This stage rapidly progresses to deep anesthesia with concomitant reduction in the blood pressure. A few seconds later, breathing stops, due to depression of the medullary respiratory center; encephalographic activity becomes isoelectric, indicating cerebral death; and then cardiac activity ceases.

Phenytoin sodium exerts its effect during the deep anesthesia stage caused by the pentobarbital sodium. This ingredient, due to its cardiotoxic properties, hastens the stoppage of electrical activity in the heart.

**INDICATIONS:** For use in dogs for humane, painless, and rapid euthanasia.

**WARNING:** For canine euthanasia only. Must not be used for therapeutic purposes. Do not use in animals intended for food.

<p><b>ENVIRONMENTAL HAZARD:</b> This product is toxic to wild life. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with state and local laws, to prevent consumption of carcass material by scavenging wildlife.</p>
---

**HUMAN WARNING:** Caution should be exercised to avoid contact of the drug with open wounds or accidental self-inflicted injections. Keep out of reach of children. If eye contact, flush eyes with water and seek medical attention.

**PRECAUTIONS:** Euthanasia may sometimes be delayed in dogs with severe cardiac or circulatory deficiencies. This may be explained by the impaired movement of the drug to its site of action. An occasional dog may elicit reflex responses manifested by motor movement; however, an unconscious animal does not experience pain, because the cerebral cortex is not functioning.

When restraint may cause the dog pain, injury, or anxiety, or danger to the person making the injection, prior use of tranquilizing or immobilizing drugs may be necessary.

**DOSAGE:** Dogs: 1 mL for each 10 pounds of body weight.

**ADMINISTRATION:** Intravenous injection is preferred. Intracardiac injection may be made when intravenous injection is impractical, as in a very small dog, or in a comatose dog with impaired vascular functions. Good injection skill is necessary for intracardiac injection.

The calculated dose should be given in a single bolus injection.

For intravenous injection, a needle of sufficient gauge to ensure intravenous placement of the entire dose should be used. The use of a Luer-Lok<sup>®</sup> syringe is recommended to prevent accidental exposure to needle/syringe separation.

**HOW SUPPLIED:** Euthanasia III Solution is available in 100 mL multiple-dose vials.

Manufactured by a non-sterilizing process.

**STORAGE:** Store between 15° and 30°C (59°F and 86°F).

**Reorder #024352**

For additional information about adverse drug experience reporting for animal contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/AnimalVeterinary/SafetyHealth>

**Questions?**

(855) 724 -3461

Distributed by:  
Covetrus North America  
400 Metro Place North  
Dublin, OH 43017

**covetrus.com**

AH-024352-L-01

REV: 0819

Manufactured by a non-sterilizing process.  
Multiple dose vial.  
**WARNING:** For canine euthanasia only. Must not be used for therapeutic purposes. Do not use in animals intended for food.  
**HUMAN WARNING:** Refer to package insert for important human risk information.  
Store between 15° and 30°C (59° and 86°F).

**ENVIRONMENTAL HAZARD:** This product is toxic to wildlife. Birds and mammals feeding on treated animals may be killed. Euthanized animals must be properly disposed of by deep burial, incineration, or other method in compliance with state and local laws, to prevent consumption of carcass material by scavenging wildlife.

NDC: 11695-4860 -1

# Euthanasia III Solution



**For dogs only.**

**CAUTION:** Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ANADA #200-280, Approved by the FDA

**Net contents: 100 mL**

**Each mL contains:** Active ingredients: 390 mg pentobarbital sodium (barbituric acid derivative), 50 mg phenytoin sodium. Inactive ingredients: 10% ethyl alcohol, 18% propylene glycol, 0.003688 mg rhodamine B, 2% benzyl alcohol (preservative), purified water q.s. sodium hydroxide and/or hydrochloric acid may be added to adjust pH.

**FOR INTRAVENOUS OR INTRACARDIAC USE.** Read product information sheet carefully. See warnings on left panel.



**Reorder #024352**

For additional information about adverse drug experience reporting for animals contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/AnimalVeterinary/SafetyHealth>

Questions?  
(855) 724-3461

Distributed by:  
Covetrus North America  
400 Metro Place North  
Dublin, OH 43017  
covetrus.com

AH-024352-L-01  
REV: 0819

Lot # /  
Exp. Date:

## EUTHANASIA III SOLUTION

euthanasia injection, solution

### Product Information

<b>Product Type</b>	PRESCRIPTION ANIMAL DRUG	<b>Item Code (Source)</b>	NDC:11695-4860
<b>Route of Administration</b>	INTRAVENOUS, INTRACARDIAC	<b>DEA Schedule</b>	CIII

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>PENTOBARBITAL SODIUM</b> (UNII: NJJ0475N0S) (PENTOBARBITAL - UNII:I4744080IR)	PENTOBARBITAL SODIUM	390 mg in 1 mL
<b>PHENYTOIN SODIUM</b> (UNII: 4182431BJH) (PHENYTOIN - UNII:6158TKW0C5)	PHENYTOIN SODIUM	50 mg in 1 mL

### Product Characteristics

<b>Color</b>	red (bluish-red)	<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>		<b>Imprint Code</b>	
<b>Contains</b>			

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:11695-4860-1	100 mL in 1 VIAL, MULTI-DOSE		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200280	10/25/2019	

---

**Registrant** - Med-Pharmex, Inc (025353699)

**Establishment**

Name	Address	ID/FEI	Business Operations
Med-Pharmex, Inc		025353699	manufacture

Revised: 1/2020

Covetrus North America